Episode Details

In this episode of Global Economic Press, Alex Brady discusses a significant development in the biopharmaceutical industry with the appointment of Gavin Barnard, Doctor of Philosophy, as Chief Scientific Officer at ATUM. This strategic move is expected to accelerate the development timelines for biologics, a critical area in biotechnology innovation. Doctor Barnard brings over two decades of experience from leading companies such as Genentech and Eli Lilly and Company, making him well-suited to advance ATUM's scientific strategy and technology initiatives. His expertise in navigating biotherapeutics from early-stage discovery to clinical manufacturing positions him as an ideal leader to drive ATUM's integrated service offerings forward.

As Chief Scientific Officer, Doctor Barnard will oversee key areas such as Hit-to-Lead Services, Cell Line Development, and the Complex Modalities Roadmap. These initiatives aim to enhance ATUM's capabilities in drug candidate assessment, maintain the growth of their Leap-In Transposase technology, and support complex modalities like multispecifics and Antibody-Drug Conjugates. Jeremy Minshull, Doctor of Philosophy, Chief Executive Officer of ATUM, expressed confidence in Doctor Barnard's ability to translate technical knowledge into effective solutions, ensuring continued innovation. Doctor Barnard himself is excited to join ATUM's team and help clients accelerate promising therapies into clinical stages. For more information about ATUM and their services, visit their website at https://atum.bio.